Related Experiment Video
Updated: Aug 12, 2026
09:07
An Orthotopic Model of Murine Bladder Cancer
Published on: February 6, 2011
Chemotherapy before radiotherapy for T3 bladder cancer. A pilot study
British Journal of Urology
|August 1, 1985
Summary
This pilot study investigated initial chemotherapy followed by radiotherapy for T3 bladder cancer. The combination did not improve outcomes compared to radiotherapy alone, with a median survival of 27 months.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Oncology
Background:
- Stage T3 bladder cancer requires effective treatment strategies.
- Neoadjuvant chemotherapy followed by radiotherapy is a potential approach.
Purpose of the Study:
- To evaluate the efficacy and safety of neoadjuvant chemotherapy (cyclophosphamide, methotrexate, 5-fluorouracil) followed by radiotherapy in patients with stage T3 bladder cancer.
Main Methods:
- Pilot study involving 17 patients with stage T3 bladder cancer.
- Administered four courses of cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
- Followed by megavoltage radiotherapy (6000 cGy) to the bladder.
Main Results:
- Chemotherapy was well-tolerated and did not increase radiotherapy toxicity.
- Of 12 assessable patients, 9 showed no objective response, and 3 progressed.
- Median survival was 27 months, with a 3-year survival rate of 26%.
Conclusions:
- Initial chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil followed by radiotherapy did not demonstrate improved outcomes for T3 bladder cancer.
- The treatment regimen did not appear to enhance the results typically achieved with radiotherapy alone.
